Abstract
Tumor cell-induced platelet aggregation (TCIPA) accelerates malignant melanoma (MM) lung metastasis via tumor-educated platelets (TEPs). These platelets trigger the recruitment of tumor-associated macrophages (TAMs), promote their polarization toward an immunosuppressive M2 phenotype, and remodel the suppressive tumor immune microenvironment (TIME) in lung metastases.
Introduction
Malignant melanoma (MM) is notoriously aggressive once it enters the bloodstream, a process known as hematogenous metastasis. Clinicians have long observed "paraneoplastic thrombocytosis"—an abnormally high platelet count—in cancer patients, which often correlates with poor prognosis. While platelets were traditionally thought to provide simple physical protection for circulating tumor cells, this study explores their more complex role as a "recruitment agency" for immune cells that facilitate metastasis and immune evasion.
Methods
To isolate the effects of platelets, researchers developed a specialized TCIPA metastatic melanoma model (B16+PLT) by injecting mice with a 100:1 ratio of platelets to B16 melanoma cells. The formation of micro-thrombi in lung tissue was confirmed using Modified Martius Scarlet Blue (MSB) staining. The researchers then employed Flow Cytometry (FCM) and Immunohistochemistry (IHC) to map the immune landscape, specifically identifying M2-type macrophages and PD-L1 expression. Mechanistic studies included Transwell migration assays and ELISA to measure the secretion of chemokines like CCL2 and SDF-1 from tumor-educated platelets (TEPs).
Results
The TCIPA model demonstrated a significant increase in metastatic burden. Mice in the B16+PLT group exhibited substantially higher lung weights compared to the standard B16 model (375.56 mg vs. 222.78 mg), indicating extensive metastatic colonization.
Interestingly, the pro-metastatic effect of platelets appeared to be specific to the metastatic site rather than a general enhancement of primary tumor growth. Longitudinal tracking of tumor volume showed that the B16+PLT group did not exhibit accelerated primary tumor expansion compared to the B16 group, suggesting the influence of platelets is mediated through the microenvironment of distant organs.
Analysis of the lung microenvironment revealed that TCIPA nearly doubled the population of M2-type TAMs. This recruitment was driven by a spike in chemokines like CCL2 and SDF-1 released by TEPs. These recruited macrophages showed a massive upregulation of PD-L1, creating an immunosuppressive shield. Therapeutic intervention using an anti-PD-L1 antibody reduced the lung metastatic burden by approximately 23.7%, confirming the role of platelet-induced immune suppression.
Discussion
This study highlights that platelets act as critical signaling hubs. When "educated" by tumor cells, they become TEPs that pump out chemokines to signal macrophages to swarm metastatic sites. This "M2 switch"—flipping macrophages into a growth-promoting, immune-suppressive state—effectively cloaks the tumor from the host's immune defenses. These findings suggest that targeting the platelet-macrophage axis could be a powerful strategy to prevent metastasis in high-risk melanoma patients, particularly those who have become resistant to standard immunotherapy.
Conclusion
TCIPA-mediated macrophage recruitment and polarization represent a key mechanism of hematogenous metastasis in malignant melanoma. By remodeling the TIME into a "safe harbor," platelets play a decisive role in cancer progression, offering new targets for therapeutic intervention in advanced melanoma.
Summary updated